U.S. markets closed
  • S&P Futures

    4,071.25
    +12.50 (+0.31%)
     
  • Dow Futures

    33,622.00
    +114.00 (+0.34%)
     
  • Nasdaq Futures

    13,040.25
    +41.75 (+0.32%)
     
  • Russell 2000 Futures

    2,144.30
    +12.80 (+0.60%)
     
  • Crude Oil

    65.72
    -0.36 (-0.54%)
     
  • Gold

    1,816.90
    -5.90 (-0.32%)
     
  • Silver

    27.17
    -0.07 (-0.25%)
     
  • EUR/USD

    1.2088
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.6950
    +0.0710 (+4.37%)
     
  • Vix

    27.59
    +5.75 (+26.33%)
     
  • GBP/USD

    1.4071
    +0.0014 (+0.10%)
     
  • USD/JPY

    109.5480
    -0.1120 (-0.10%)
     
  • BTC-USD

    50,127.16
    -7,141.76 (-12.47%)
     
  • CMC Crypto 200

    1,369.06
    -194.77 (-12.45%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    27,709.62
    -437.89 (-1.56%)
     

Recap: Regenxbio Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 72.22% over the past year to ($1.24), which missed the estimate of ($0.43).

Revenue of $21,445,000 rose by 82.23% year over year, which missed the estimate of $61,500,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Regenxbio hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Mar 01, 2021

View more earnings on RGNX

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/wux4dg9b

Technicals

52-week high: $50.26

52-week low: $20.03

Price action over last quarter: Up 46.54%

Company Overview

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.